- Home
- LSTA vs TPST Comparison
LSTA vs TPST Comparison
Compare LSTA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | TPST |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 15.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LSTA | TPST |
|---|---|---|
| Price | $2.06 | $2.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.50 | $12.50 |
| AVG Volume (30 Days) | 33.4K | ★ 74.3K |
| Earning Date | 02-26-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,070,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $2.75 |
| 52 Week High | $4.11 | $13.26 |
Technical Indicators
Market Signals| Indicator | LSTA | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 32.97 |
| Support Level | $1.84 | $2.80 |
| Resistance Level | $2.12 | $3.04 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 63.08 | 42.04 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.